prikaz prve stranice dokumenta The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status
  Preuzmi
PDF 756.69 KB
Znanstveni rad - Izvorni znanstveni rad
The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status
Journal of Clinical Medicine, 13 (2024), 24; 7717. https://doi.org/10.3390/jcm13247717
Fodor Duric, Ljiljana; Belčić, Velimir; Oberiter Korbar, Anja; Ćurković, Sanja; Vujičić, Božidar; Gulin, Tonko; Muslim, Jelena; Gulin, Matko; Grgurević, Mladen; Catic Cuti, Edina

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Fodor Duric, Lj., Belčić, V., Oberiter Korbar, A., Ćurković, S., Vujičić, B., Gulin, T. ... Catic Cuti, E. (2024). The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status. Journal of Clinical Medicine, 13. (24). doi: 10.3390/jcm13247717

Fodor Duric, Ljiljana, et al. "The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status." Journal of Clinical Medicine, vol. 13, br. 24, 2024. https://doi.org/10.3390/jcm13247717

Fodor Duric, Ljiljana, Velimir Belčić, Anja Oberiter Korbar, Sanja Ćurković, Božidar Vujičić, Tonko Gulin, Jelena Muslim, Matko Gulin, Mladen Grgurević i Edina Catic Cuti. "The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status." Journal of Clinical Medicine 13, br. 24 (2024). https://doi.org/10.3390/jcm13247717

Fodor Duric, Lj., et al. (2024) 'The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status', Journal of Clinical Medicine, 13(24). doi: 10.3390/jcm13247717

Fodor Duric Lj, Belčić V, Oberiter Korbar A, Ćurković S, Vujičić B, Gulin T, i sur.. The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status. Journal of Clinical Medicine [Internet]. 18.12.2024. [pristupljeno 26.12.2024.];13(24). doi: 10.3390/jcm13247717

Lj. Fodor Duric, et al., "The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status", Journal of Clinical Medicine, vol. 13, br. 24, Prosinac 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:148388. [Citirano: 26.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:148388
Podaci o radu
Naslov (engleski)The Role of SHBG as a Marker in Male Patients with Metabolic-Associated Fatty Liver Disease: Insights into Metabolic and Hormonal Status
AutorLjiljana Fodor Duric
AutorVelimir Belčić
AutorAnja Oberiter Korbar
AutorSanja Ćurković
AutorBožidar Vujičić
AutorTonko Gulin
AutorJelena Muslim
AutorMatko Gulin
AutorMladen Grgurević
AutorEdina Catic Cuti
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za urologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Metabolic-associated fatty liver disease (MAFLD) is a spectrum of liver diseases linked to insulin resistance (IR), type 2 diabetes, and metabolic disorders. IR accelerates fat accumulation in the liver, worsening MAFLD. Regular physical activity and weight loss can improve liver function, reduce fat, and lower cardiovascular risk. This study examines the role of sex hormone-binding globulin (SHBG) in MAFLD, focusing on its potential as a biomarker and its relationship with insulin resistance. Methods: The study included 98 male patients (ages 30–55) with MAFLD, identified through systematic examinations, and 74 healthy male controls. All participants underwent abdominal ultrasound and blood tests after fasting, assessing markers such as glucose, liver enzymes (AST, ALT, γGT), lipids (cholesterol, triglycerides), insulin, SHBG, estradiol, and testosterone. SHBG levels were analyzed in relation to body mass index (BMI) and age. Results: A significant association was found between low SHBG levels and the presence of fatty liver. Individuals with MAFLD had lower SHBG levels compared to controls. BMI and age were key factors influencing SHBG, with higher BMI linked to lower SHBG in younger men, while SHBG remained stable in older individuals regardless of BMI. Conclusion: SHBG may serve as a valuable biomarker for early detection and risk assessment of MAFLD. The complex relationship between SHBG, BMI, and age highlights the importance of considering both hormonal and metabolic factors when assessing fatty liver risk. Our findings support the need for comprehensive metabolic evaluations in clinical practice.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Clinical Medicine
Brojčani podacivol. 13, br. 24, 7717
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm13247717
URN:NBNurn:nbn:hr:184:148388
Datum objave publikacije2024-12-18
URL dokumentahttps://www.mdpi.com/2077-0383/13/24/7717
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-12-23 07:51:11